TransCode to Detail TTX-MC138 Phase 2a Trial, Pipeline and Capital Strategy on June 18
RNAZ•TransCode Therapeutics will host a live R&D webcast on June 18 at 10:00 a.m. ET to discuss its recently initiated TTX-MC138 Phase 2a trial in ctDNA-positive colorectal cancer, with updates on its three-platform RNA therapeutics and immuno-oncology pipeline. The webcast will also cover capital strategy and long-term investment thesis.
1. Webcast Logistics
TransCode Therapeutics will host a live R&D webcast on June 18, 2026, from 10:00 to 11:15 a.m. Eastern Time, with open access registration starting June 11 and a replay available on its website.
2. TTX-MC138 Phase 2a Trial
The webcast will outline the recently initiated TTX-MC138 Phase 2a antagomiR trial in ctDNA-positive colorectal cancer, detailing the trial design, enrollment criteria and planned strategic path forward.
3. Pipeline Overview and Capital Strategy
Management will present updates on its three-platform pipeline in RNA therapeutics and immuno-oncology, discuss capital strategy and financial position, and articulate the long-term investment thesis with insights from internal and external experts.
